Please Note: Microsoft has ended support of its older browsers as of January 2016. If you are seeing this message, you are viewing the site on an unsupported version of Internet Explorer (IE10 or older). To properly view this website, please upgrade your version of IE or access this site using a different browser. Thank you.
Sign InDues Join Privacy Contact Search
Home News Scrip

Scrip

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below.

John Lezcano
Corporate Account Manager
M: (631) 807-4971
John.lezcano@informa.com

Pharma intelligence | informa
P: (212) 652-2678
pharmaintelligence.informa.com

Scrip
Friday, June 5, 2020
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for...
Friday, June 5, 2020
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all...
Friday, June 5, 2020
The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which...
Friday, June 5, 2020
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
Friday, June 5, 2020
Friday, June 5, 2020
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal...
Thursday, June 4, 2020
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new...
Thursday, June 4, 2020
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign...
Thursday, June 4, 2020
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.
Thursday, June 4, 2020
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice...